Gilead Sciences, Inc. $GILD Stock Acquired by RHS Financial LLC

Key Points

• RHS Financial increased its Gilead Sciences stake by 584.1% in the third quarter, buying 20,877 additional shares for a total holding of 24,451 shares valued at approximately $3.64 million.
• Institutional investors own 83.67% of Gilead’s shares, while company insiders sold 105,000 shares worth about $14.94 million over the past 90 days.
• Gilead reported quarterly revenue of $7.8 billion, beating estimates, and pays an annualized dividend of $3.28 per share. Analysts maintain a “Moderate Buy” consensus with an average price target of $159.33 versus the reported share price of $147.92.

RHS Financial LLC increased its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 584.1% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 24,451 shares of the biopharmaceutical company's stock after purchasing an additional 20,877 shares during the period. Gilead Sciences accounts for approximately 1.1% of RHS Financial LLC's investment portfolio, making the stock its 27th biggest position. RHS Financial LLC's holdings in Gilead Sciences were worth $3,644,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. BlackRock Inc. purchased a new stake in Gilead Sciences during the 2nd quarter worth approximately $15,393,785,000. Legal & General Group Plc acquired a new position in shares of Gilead Sciences during the second quarter valued at approximately $1,316,606,000. Deutsche Bank AG acquired a new position in shares of Gilead Sciences during the second quarter valued at approximately $918,387,000. Jupiter Topco LLC purchased a new position in shares of Gilead Sciences in the second quarter valued at approximately $448,021,000. Finally, Mitsubishi UFJ Asset Management Co. Ltd. purchased a new position in shares of Gilead Sciences in the second quarter valued at approximately $398,905,000. 83.67% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, insider Johanna Mercier sold 3,000 shares of the stock in a transaction that occurred on Tuesday, September 15th. The stock was sold at an average price of $144.22, for a total value of $432,660.00. Following the completion of the sale, the insider owned 116,684 shares of the company's stock, valued at approximately $16,828,166.48. This trade represents a 2.51% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew Dickinson sold 3,000 shares of Gilead Sciences stock in a transaction that occurred on Tuesday, September 15th. The stock was sold at an average price of $145.29, for a total value of $435,870.00. Following the transaction, the chief financial officer owned 164,096 shares in the company, valued at approximately $23,841,507.84. The trade was a 1.80% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 105,000 shares of company stock valued at $14,940,540. Insiders own 0.30% of the company's stock.

Gilead Sciences Stock Down 1.7%

Shares of NASDAQ GILD opened at $147.92 on Wednesday. Gilead Sciences, Inc. has a 12-month low of $114.02 and a 12-month high of $157.29. The stock has a market cap of $183.41 billion, a PE ratio of -55.40 and a beta of 0.31. The company has a current ratio of 1.27, a quick ratio of 1.09 and a debt-to-equity ratio of 2.03. The company has a 50-day moving average of $145.77 and a 200 day moving average of $136.87.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share for the quarter, topping analysts' consensus estimates of ($7.25) by $0.50. Gilead Sciences had a negative net margin of 10.64% and a negative return on equity of 2.11%. The business had revenue of $7.80 billion for the quarter, compared to analyst estimates of $7.40 billion. During the same period last year, the company posted $2.01 EPS. The business's revenue was up 10.6% on a year-over-year basis. As a group, sell-side analysts predict that Gilead Sciences, Inc. will post -0.47 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, September 29th. Stockholders of record on Tuesday, September 15th were given a $0.82 dividend. The ex-dividend date was Tuesday, September 15th. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.2%. Gilead Sciences's dividend payout ratio is -122.85%.

Key Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Analysts remain bullish on Gilead, highlighting the company among attractive healthcare stocks. The positive view reflects Gilead’s HIV, liver-disease and oncology franchises, as well as its longer-term growth prospects. Analysts Are Bullish on These Healthcare Stocks: BioNTech SE (BNTX), Gilead Sciences (GILD)
• Positive Sentiment: Bank of America said survey results support a favorable long-term outlook for Yeztugo, Gilead’s HIV-prevention drug. Strong adoption potential could provide an additional growth driver for the company’s HIV portfolio. Gilead Sciences' Yeztugo Survey Supports Long-Term Growth Outlook, BofA Says
• Positive Sentiment: Erste Group Bank modestly raised its FY2027 EPS forecast for Gilead to $9.90 from $9.88, signaling confidence in the company’s future profitability. Erste Group Bank Raises Gilead Sciences EPS Estimate
• Neutral Sentiment: Recent comparisons with GRAIL and Vertex Pharmaceuticals provide valuation and operating-context analysis but do not identify a specific new catalyst for GILD. Contrasting GRAIL and Gilead Sciences Gilead Sciences versus Vertex Pharmaceuticals
• Negative Sentiment: Gilead’s upcoming third-quarter earnings report is expected to show a double-digit year-over-year EPS decline. That forecast is weighing on sentiment despite optimism about the company’s longer-term pipeline and product growth. Earnings Preview: What to Expect From Gilead Sciences’ Report

Analysts Set New Price Targets

A number of brokerages have recently issued reports on GILD. Royal Bank Of Canada lifted their price target on Gilead Sciences from $123.00 to $126.00 and gave the stock a "sector perform" rating in a research note on Thursday, October 8th. Barclays dropped their price target on Gilead Sciences from $155.00 to $145.00 and set an "equal weight" rating for the company in a research report on Wednesday, July 29th. Leerink Partners downgraded Gilead Sciences from an "outperform" rating to a "market perform" rating and reduced their price objective for the company from $146.00 to $127.00 in a research note on Tuesday, July 21st. HSBC raised their price objective on Gilead Sciences from $155.00 to $175.00 and gave the company a "buy" rating in a report on Thursday, September 10th. Finally, Bank of America reaffirmed a "buy" rating and set a $164.00 target price on shares of Gilead Sciences in a research note on Monday. Twenty-three research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat, Gilead Sciences currently has an average rating of "Moderate Buy" and an average target price of $159.33.

Gilead Sciences Profile

Gilead Sciences, Inc NASDAQ: GILD is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. Its research and commercial activities focus primarily on virology, including HIV, hepatitis B and hepatitis C, as well as oncology, inflammation and other areas of significant unmet medical need.

Gilead's portfolio includes HIV treatments such as Biktarvy, Descovy, Genvoya and Sunlenca; hepatitis therapies including Epclusa, Harvoni and Vemlidy; and Veklury (remdesivir), an antiviral used to treat COVID-19 in certain patients.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.